RxDoctor Payments Data

James West, MD

Internal Medicine · Baton Rouge, LANPI 1477574002

Payments from drug & device makers

$383in general payments, 2019–2025

Across 24 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$259
  • Bayer$44
  • Lilly USA, LLC$34
  • AstraZeneca$17
  • Dexcom, Inc.$15
  • Amgen$14

What the payments were for

  • Food & beverage$35893%
  • Education$267%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$383 in reported general payments places this provider in the 45th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$189,851
Medicare patients
354
Services billed
9,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$158,925
JardianceEmpagliflozin215$154,909
MounjaroTirzepatide115$125,253
EliquisApixaban84$81,951
JanuviaSitagliptin Phosphate52$54,194
BiktarvyBictegrav/Emtricit/Tenofov Ala12$45,063
LinzessLinaclotide47$27,661
XareltoRivaroxaban25$25,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$21,264
KerendiaFinerenone24$19,959
Tresiba Flextouch U-100Insulin Degludec25$18,976
Lantus SolostarInsulin Glargine,hum.Rec.Anlog109$16,469
NexletolBempedoic Acid25$15,247
SynthroidLevothyroxine Sodium261$14,340
FarxigaDapagliflozin Propanediol16$14,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$34$125,253115 claims
BayerKerendia$44$19,95924 claims
AstraZenecaFarxiga$17$14,29316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →